Department of Cell Biology, Cell Engineering Research Centre, State Key Laboratory of Cancer Biology, State Key Discipline of Cell Biology, Fourth Military Medical University, Xi'an, China.
Cell Death Differ. 2012 Nov;19(11):1779-90. doi: 10.1038/cdd.2012.60. Epub 2012 May 18.
The unfolded protein response (UPR) is generally activated in solid tumors and results in tumor cell anti-apoptosis and drug resistance. However, tumor-specific UPR transducers are largely unknown. In the present study, we identified CD147, a cancer biomarker, as an UPR inducer in hepatocellular carcinoma (HCC). The expression of the major UPR target, Bip, was found to be positively associated with CD147 in human hepatoma tissues. By phosphorylating FAK and Src, CD147-enhanced TFII-I tyrosine phosphorylation at Tyr248. CD147 also induced p-TFII-I nuclear localization and binding to the Bip promoter where endoplasmic reticulum (ER) stress response element 1 (ERSE1) (-82/-50) is the most efficient target of the three ERSEs, thus increasing transcription of Bip. Furthermore, by inducing UPR, CD147 inhibited HCC cell apoptosis and decreased cell Adriamycin chemosensitivity, thus decreasing the survival rate of hepatoma-bearing nude mice. Together, these results reveal pivotal roles for CD147 in modulating the UPR in HCC and raise the possibility that CD147 is a target that promotes HCC cell apoptosis and increases the sensitivity of tumors to anti-cancer drugs. Therefore, CD147 inhibition provides an opportunity to enhance the efficacy of existing agents and represents a novel target for HCC treatment.
未折叠蛋白反应(UPR)通常在实体瘤中被激活,导致肿瘤细胞抗凋亡和耐药。然而,肿瘤特异性的 UPR 转导物在很大程度上是未知的。在本研究中,我们鉴定了 CD147,一种癌症生物标志物,作为肝癌(HCC)中的 UPR 诱导物。发现主要 UPR 靶标 Bip 的表达与人肝癌组织中的 CD147 呈正相关。CD147 通过磷酸化 FAK 和 Src,增强 TFII-I 的酪氨酸磷酸化,在 Tyr248 处磷酸化。CD147 还诱导 p-TFII-I 核定位并与 Bip 启动子结合,内质网(ER)应激反应元件 1(ERSE1)(-82/-50)是三个 ERSE 中最有效的靶标,从而增加 Bip 的转录。此外,通过诱导 UPR,CD147 抑制 HCC 细胞凋亡并降低细胞阿霉素化疗敏感性,从而降低荷肝癌裸鼠的存活率。总之,这些结果揭示了 CD147 在调节 HCC 中 UPR 中的关键作用,并提出了 CD147 是促进 HCC 细胞凋亡和增加肿瘤对抗癌药物敏感性的靶标的可能性。因此,CD147 抑制为增强现有药物的疗效提供了机会,代表了 HCC 治疗的一个新靶点。